Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of ...

An Ancillary Study of the STAMPEDE Docetaxel Trials Ruth Langley presented results from a phase 3 trial comparing transdermal estradiol to LHRH agonists for androgen suppression in M0 prostate cancer.

Investigators report that estradiol works as well as luteinizing hormone–releasing hormone agonists for testosterone suppression and have a much better side-effect profile.

Alarming Rise in Rates of Advanced Prostate Cancer in California Feb. 3, 2025 — The incidence of advanced prostate cancer in California rose markedly in the decade since doctors stopped ...

Although carbon ion radiation led to a decline in urinary function among patients with prostate cancer, function returned to normal after three months. Among those with intermediate-risk prostate ...

Recently, licensed and emerging treatments for metastatic castrate-resistant prostate cancer are transforming the prognosis for men whose disease has already progressed during or after docetaxel ...

Feb. 18, 2025 — The immune systems of cancer patients are highly disrupted, with those who have a higher number of immune cells in their blood having a better survival rate, finds a new study ...

it has found no evidence that GLP-1 agonist drugs such as Novo Nordisk’s Ozempic and Eli Lilly’s Trulicity can cause cancer of the thyroid. Six months ago, the Pharmacovigilance Risk ...

"Patients with metastatic hormone-sensitive prostate cancer benefited from treatment with darolutamide plus ADT and docetaxel regardless of age," said Joan Carles, MD, PhD.

More than 67,000 Americans will be diagnosed with pancreatic cancer this year. Learn more about the disease and how PanCAN can help.